Executive Summary
Typical Pulmonary Carcinoid (TPC) is a well-differentiated, low-grade neuroendocrine neoplasm (NET) of the lung. It represents the most indolent end of the pulmonary neuroendocrine tumor spectrum. While classified as malignant due to its potential for metastasis, it carries an excellent prognosis compared to other lung cancers. This guide covers epidemiology, pathology, clinical presentation, diagnostic workup, staging, treatment algorithms, and long-term surveillance.
TPC is a distinct clinical entity—not “benign” and not “small cell lung cancer.” Accurate histological distinction from Atypical Carcinoid (AC) and Large/Small Cell Neuroendocrine Carcinoma dictates management and predicts survival.
1. Epidemiology & Risk Factors
| Feature | Typical Carcinoid | Atypical Carcinoid | Small Cell / Large Cell NEC |
|---|---|---|---|
| Incidence | ~1.5–2 per 100,000/year | ~0.2–0.3 per 100,000/year | ~13 per 100,000/year (SCLC) |
| % of Lung Cancers | 1–2% | <0.5% | ~15–20% (combined) |
| Median Age at Dx | 45–55 years | 55–65 years | 65–75 years |
| Sex Predilection | Slight Female > Male | Slight Female > Male | Male > Female (historically) |
| Smoking Association | Weak / None | Moderate | Strong |
| Hereditary Links | MEN1 Syndrome (5–10% of MEN1 pts) | Rare | Rare |
Risk Factors & Associations
- Multiple Endocrine Neoplasia Type 1 (MEN1): Patients with MEN1 gene mutations have a significantly elevated lifetime risk (up to 10%) of developing bronchial carcinoids, often multiple and peripheral.
- Airway Obstruction: Chronic inflammation from long-standing obstruction (e.g., post-tuberculous stenosis) has been hypothesized as a co-factor, though causality is unproven.
- Radiation Exposure: Prior thoracic radiotherapy may slightly increase risk decades later.
- No Dietary/Lifestyle Links: Unlike adenocarcinoma or squamous cell carcinoma, tobacco smoke is not a primary driver for typical carcinoid.
2. Pathology & Molecular Biology: The “Gold Standard” Diagnosis
Diagnosis relies entirely on histopathological examination of tissue (biopsy or resection). Cytology (brushings/washings) is often insufficient for grading.
WHO 2021 / 2015 Diagnostic Criteria (The “Big Two”)
| Criterion | Typical Carcinoid (TC) | Atypical Carcinoid (AC) |
|---|---|---|
| Mitotic Count (per 2 mm² / 10 HPF) | < 2 | 2 – 10 |
| Necrosis | Absent (no necrosis) | Present (focal, often punctate) |
| Cellular Morphology | Uniform, “salt-and-pepper” chromatin; organoid nesting/trabeculae | Increased cellularity, pleomorphism, rosettes possible |
| Ki-67 Proliferation Index | Usually < 5% (Not formal WHO criteria, but supportive) | Usually 5–20% (Supportive) |
⚠ Critical Distinction: The presence of even a single focus of necrosis (excluding crush artifact) upgrades the tumor to Atypical Carcinoid**, regardless of mitotic count.
Immunohistochemistry (IHC) Profile
Used to confirm neuroendocrine differentiation and exclude mimics.
| Marker | Typical Result | Clinical Utility |
|---|---|---|
| Chromogranin A | Strongly Diffuse + | Most specific NE marker; confirms dense core granules. |
| Synaptophysin | Strongly Diffuse + | Highly sensitive; confirms synaptic vesicle origin. |
| CD56 (NCAM) | Variable + | Sensitive but non-specific (positive in many carcinomas). |
| Ki-67 (MIB-1) | Low (< 5–10%) | Adjunct only. Helps separate TC/AC from High-Grade NEC (Ki-67 > 20–30%). |
| TTF-1 | Usually Negative / Focal + | Helps distinguish from Adenocarcinoma (TTF-1 strong +) & SCLC (TTF-1 +). |
| p40 / p63 | Negative | Excludes Squamous Cell Carcinoma. |
| Rb1 / p53 | Wild-type (Retained expression) | Loss suggests High-Grade NEC (SCLC/LCNEC). |
Molecular Landscape
- MEN1 Mutations: ~40–50% of sporadic TCs; ~90% in MEN1-associated tumors. Tumor suppressor gene (menin).
- Chromosomal Changes: Frequent loss of 11q22–23 (MEN1 locus), 3p, 5q, 9p, 13q, 21q.
- No Targetable Drivers: EGFR, ALK, ROS1, KRAS, BRAF mutations are exceedingly rare. PD-L1 expression is typically low.
3. Clinical Presentation: Location Dictates Symptoms
TPCs are classified by anatomic location, which drives symptomatology.
Central (Endobronchial) Tumors (~80%)
Arise in main/lobar/segmental bronchi.
- Obstructive Syndrome: Cough (often persistent >8 weeks), wheezing (monophonic), hemoptysis (25–50%), recurrent pneumonia/atelectasis (post-obstructive).
- Paraneoplastic Syndromes (Rare, <5%):
- Carcinoid Syndrome: Flushing, diarrhea, valvular heart disease (tricuspid/pulmonic). Requires liver mets (serotonin bypasses pulmonary metabolism). Very rare in TC without mets.
- Cushing Syndrome (ACTH): Ectopic ACTH production → hypokalemia, hyperglycemia, hypertension. More common in AC/LCNEC but seen in TC.
- Acromegaly (GHRH): Rare.
Peripheral (Parenchymal) Tumors (~20%)
Arise in subsegmental bronchi / lung parenchyma.
- Often Asymptomatic: Discovered incidentally on imaging (CT screening, trauma workup).
- Local Effects: Pleural pain (if pleural invasion), dyspnea (large size), rare hemoptysis.
- Lower rate of paraneoplastic syndromes.
4. Diagnostic Workup: Step-by-Step Algorithm
Step 1: Imaging – The “Roadmap”
| Modality | Role | Key Findings (Typical Carcinoid) |
|---|---|---|
| Chest X-Ray (CXR) | Initial screen | Central: Hilar mass, atelectasis, mucoid impaction (“ice cream cone” sign).<br>Peripheral: Solitary Pulmonary Nodule (SPN), well-circumscribed, smooth/lobulated. Calcification in 10–25%. |
| Contrast-Enhanced Chest CT | Primary Staging Tool | Central: Endobronchial mass + extrinsic compression (“iceberg” effect). Enhancement is intense/homogeneous (hypervascular).<br>Peripheral: SPN, strong enhancement. Assessment of lymph nodes (short axis >10mm = suspicious). |
| MRI Chest | Problem-solving | Superior soft tissue contrast for mediastinal/vascular invasion assessment (e.g., SVC, PA, aorta). No radiation. |
| Octreotide Scan (SSTR2-SPECT/CT) | Functional Imaging | High sensitivity (~85–95%) for well-differentiated NETs. Detects occult mets, confirms SSTR expression for PRRT eligibility. |
| ⁶⁸Ga-DOTATATE PET/CT | Gold Standard Functional | Superior resolution/sensitivity vs Octreoscan. Standard for staging/restaging if available. SUVmax usually high. |
| FDG PET/CT | Limited Role | Low sensitivity for TC (low metabolic rate). High uptake suggests High-Grade transformation or Atypical Carcinoid. Useful to differentiate TC vs AC/LCNEC. |
| Bone Scan / Brain MRI | Staging | Only if symptomatic or high clinical suspicion (AC/High Grade). Low yield in asymptomatic TC. |
Step 2: Tissue Acquisition – “Tissue is the Issue”
| Approach | Indication | Diagnostic Yield | Risk / Notes |
|---|---|---|---|
| Bronchoscopy + Biopsy | Central tumors (visible endobronchial component) | High (70–90%) | Bleeding Risk: Hypervascular! Use cold forceps, electrocautery, or Argon Plasma Coagulation (APC) ready. Avoid deep forceps bites. |
| EBUS-TBNA / EUS-FNA | Mediastinal nodal staging (N2/N3) | High for nodes | Essential for staging; confirms N stage pre-op. |
| CT-Guided Core Needle Biopsy | Peripheral nodules | High (>90%) | Preferred for peripheral lesions. Risk: Pneumothorax (15–25%), hemorrhage. |
| Surgical Biopsy (VATS/Robotic) | Non-diagnostic less invasive attempts; Peripheral SPN “suspicious” | 100% (Definitive) | Diagnostic and therapeutic (wedge resection). Frozen section for margins. |
💡 Clinical Pearl: Never** perform transbronchial needle aspiration (TBNA) on a visible endobronchial carcinoid without cautery backup—life-threatening hemorrhage can occur. “Cold” forceps biopsies are safer for superficial sampling.
Step 3: Laboratory & Functional Workup
- Chromogranin A (CgA): Baseline tumor marker. Elevated in ~60–80% of metastatic disease; less sensitive for localized disease. Proton Pump Inhibitors (PPIs) cause false positives – hold 2 weeks prior.
- 24-hr Urine 5-HIAA: Gold standard for Carcinoid Syndrome. Collect with dietary restrictions (avoid serotonin-rich foods: bananas, walnuts, tomatoes, pineapple).
- Serum Serotonin: Alternative to 5-HIAA.
- ACTH / Cortisol / DHEA-S: If clinical suspicion of Ectopic Cushing’s.
- Pulmonary Function Tests (PFTs): Mandatory pre-operatively (FEV1, DLCO) to assess resection tolerance.
5. Staging: TNM 8th Edition (AJCC/UICC)
TPC uses the same TNM staging as Non-Small Cell Lung Cancer (NSCLC).
T Category (Primary Tumor)
| T Stage | Definition | Clinical Relevance |
|---|---|---|
| Tis | Carcinoma in situ (pre-invasive) | Rarely diagnosed pre-operatively. |
| T1 | ≤ 3 cm | T1a ≤1cm; T1b >1–2cm; T1c >2–3cm. |
| T2 | >3–5 cm OR involves visceral pleura, main bronchus (≥2cm from carina), atelectasis to hilum | Size or local invasion. |
| T3 | >5–7 cm OR invades chest wall, pericardium, phrenic nerve, parietal pericardium; separate nodule same lobe | Locally advanced. |
| T4 | >7 cm OR invades diaphragm, mediastinum, heart, great vessels, trachea, recurrent laryngeal nerve, esophagus, vertebral body, carina; separate nodule different ipsilateral lobe | Unresectable / Complex resection needed. |
N Category (Regional Lymph Nodes)
- N0: No regional mets.
- N1: Ipsilateral peribronchial/hilar nodes.
- N2: Ipsilateral mediastinal/subcarinal nodes.
- N3: Contralateral mediastinal/hilar/supraclavicular nodes.
M Category (Distant Metastasis)
- M0: No distant mets.
- M1a: Separate tumor nodule in contralateral lung; pleural/pericardial nodules/effusion.
- M1b: Single extrathoracic metastasis.
- M1c: Multiple extrathoracic metastases.
Stage Grouping (Prognostic)
| Stage | T | N | M | 5-Yr OS (Approx.) | 5-Yr DSS (Disease-Specific) |
|---|---|---|---|---|---|
| IA | T1a–b | N0 | M0 | 95–100% | ~100% |
| IB | T1c–T2a | N0 | M0 | 90–95% | ~98% |
| IIA | T2b | N0 | M0 | 85–90% | ~95% |
| IIB | T1–2 | N1 | M0 | 75–85% | ~85–90% |
| IIIA | T1–2 / T3 | N2 / N1–N2 | M0 | 55–70% | ~70–80% |
| IIIB | T3–T4 | N2–N3 | M0 | 40–55% | ~50–65% |
| IVA | Any | Any | M1a–b | 30–50% | Variable |
| IVB | Any | Any | M1c | <25% | Variable |
Note:** Survival for TC is significantly better than NSCLC at every stage. Nodal status (N1 vs N2) is the single most important prognostic factor after completeness of resection (R0).
6. Treatment Guidelines: Multidisciplinary Approach
Management decisions must be made in a Multidisciplinary Tumor Board (MDT) including Thoracic Surgery, Pulmonology, Medical Oncology, Radiation Oncology, Pathology, Radiology, and Nuclear Medicine.
A. Stage I–II (Resectable, N0–N1): Surgery is Curative
| Surgical Principle | Standard of Care |
|---|---|
| Approach | VATS (Video-Assisted) or Robotic preferred (less pain, faster recovery). Open thoracotomy for complex central tumors. |
| Resection Type | Lobar Resection (Lobectomy/Bilobectomy) + Systematic Mediastinal Lymph Node Dissection (MLND) is the Gold Standard. |
| Sublobar Resection (Segmentectomy/Wedge) | Considered ONLY for:<br>• Peripheral T1a/T1b (<2 cm) node-negative.<br>• Poor pulmonary reserve (FEV1/DLCO < 40–50%).<br>• MEN1 patients (lung preservation for future primaries).<br>• Margins must be > 2 cm or > tumor diameter. |
| Lymph Nodes | MLND (Station 2–9) mandatory. Sampling alone is inadequate. N1/N2 status changes adjuvant decisions. |
| Sleeve Resection | Standard for Central Tumors to avoid pneumonectomy. Bronchial/vascular sleeve preserves lung function. Equivalent oncology outcomes to pneumonectomy. |
| Pneumonectomy | Avoid if possible. High morbidity/mortality. Only if sleeve not feasible. |
Adjuvant Therapy (Post-Op)
| Scenario | Recommendation | Evidence Level |
|---|---|---|
| R0 Resection, N0 (Stage IA–IB) | Observation only. No chemo/RT. | Strong Consensus (NCCN/ENETS) |
| R0 Resection, N1 (Stage IIB) | Observation preferred. Consider adjuvant chemo (cisplatin-based) only if high-risk features (large size, young age, AC histology). | Weak / Controversial |
| R0 Resection, N2 (Stage IIIA) | Controversial. Options: Observation vs. Adjuvant Chemo (Cisplatin/Etoposide or Cisplatin/Vinorelbine) ± Radiotherapy. Discuss in MDT. | Low (Retrospective only) |
| R1/R2 (Positive Margins) | Re-resection if feasible. Definitive RT (50–60 Gy) if unresectable residual. | Consensus |
🚫 No Role for:** Neoadjuvant Chemotherapy, Targeted Therapy (TKIs), Immunotherapy (Checkpoint Inhibitors), or PRRT in resectable early-stage TC.
B. Stage III (Locally Advanced / N2–N3 / T4)
| Scenario | Primary Strategy |
|---|---|
| Potentially Resectable (N2 single station, non-bulky) | Induction Therapy → Surgery? <br>Debated. Most guidelines favor Definitive Concurrent Chemoradiation (cCRT) similar to NSCLC, or Surgery + Adjuvant RT ± Chemo if R0 achievable. MDT decision. |
| Unresectable (N3, T4 invasion, Multi-station N2) | Definitive cCRT (Cisplatin/Etoposide or Carboplatin/Paclitaxel + 60–66 Gy). |
| Superior Sulcus (Pancoast) | Induction ChemoRT → Resection (if feasible). |
C. Stage IV (Metastatic) / Recurrent Disease
Goal: Symptom control, tumor growth stabilization, quality of life. Cure is rare.
1. Oligometastatic Disease (≤ 3–5 mets, controllable primary)
- Aggressive Local Therapy: Resection (Primary + Mets) or SBRT (Stereotactic Body RT) to all sites.
- Evidence: Retrospective series show prolonged survival (5-yr OS 40–60%).
- Candidate Selection: Long disease-free interval, controlled primary, good PS.
2. Systemic Therapy Options (Sequential Approach)
| Line | Agent / Regimen | Key Data / Indication | Response Rate (ORR) | Median PFS |
|---|---|---|---|---|
| 1st: Symptom Control (Carcinoid Syndrome) | Long-acting Somatostatin Analog (SSA)<br>• Octreotide LAR 30mg q28d<br>• Lanreotide 120mg q28d | PROMID / CLARINET (extrapolated from GI NETs). Controls flushing/diarrhea. Antiproliferative effect (stable disease). | < 5% (Tumor shrinkage) | ~20–30 mo (TTP) |
| 2nd: Tumor Growth Control (Progressive on SSA / High Burden) | Everolimus (mTOR inhibitor)<br>10 mg PO daily | LUNA / RADIANT-4 (Subgroup analysis). FDA/EMA Approved for Progressive Lung NET. | ~2–5% | ~9–11 mo |
| 3rd: Progressive / High Ki-67 (near 10%) / Bulky | Peptide Receptor Radionuclide Therapy (PRRT)<br>⁹⁰Lu-DOTATATE (4 cycles q8wks) | NETTER-1 (Midgut) + Compuse/Registry data (Lung). Requires SSTR+ on DOTATATE PET. | ~15–30% | ~20–30 mo |
| 4th: Chemotherapy (Rapid progression / High Grade features / SSTR-negative) | CAPTEM (Capecitabine + Temozolomide)<br>or Cisplatin/Etoposide (if AC/High Grade features) | ECOG-ACRIN E2211 / Retrospective series. CAPTEM preferred for better toxicity profile. | ~20–40% (CAPTEM) | ~12–18 mo |
| Investigational | Clinical Trials<br>(Belzutifan/HIF-2α, Immune combos, Novel PRRT isotopes, CDK4/6 inhibitors) | Strongly Recommended at all lines if available. | N/A | N/A |
3. Liver-Directed Therapy (Liver-Dominant Mets)
- Hepatic Artery Embolization (TAE/TACE/TARE/Y-90): For symptomatic hormone syndrome or tumor bulk uncontrolled by SSA. High symptom response (70–90%). Preserves liver function.
- Liver Resection: If oligometastatic (<4 lesions, unilateral, R0 feasible).
4. Bone Mets / Brain Mets
- Bone: Bisphosphonates (Zoledronic acid) / Denosumab + SBRT for painful/weight-bearing lesions.
- Brain: SBRT (SRS) preferred. WBRT avoided if possible (neurotoxicity). Surgery for solitary symptomatic lesion.
7. Surveillance & Long-Term Follow-Up
Rationale: High cure rate for early stage, but late recurrences occur (up to 10–15 years). Second primary lung cancers increased risk (especially post-RT).
Surveillance Schedule (Post-Curative Resection)
| Timeframe | History & Physical | Chest CT (Contrast) | Functional Imaging | Labs | Bronchoscopy |
|---|---|---|---|---|---|
| Year 1–2 | Every 3–6 months | Every 6 months | ⁶⁸Ga-DOTATATE PET/CT at 6–12 mo (Baseline) | CgA, 5-HIAA q6–12mo | At 6 & 12 mo (Central tumors) |
| Year 3–5 | Every 6 months | Every 6–12 months | If CgA rising / CT equivocal | CgA, 5-HIAA q12mo | As clinically indicated |
| Year 5–10+ | Annually | Annually (Low-dose CT acceptable) | Rarely needed | CgA q12mo | Not routine |
Special Populations: MEN1 Patients: Lifelong annual Chest CT + DOTATATE PET; aggressive screening for other MEN1 manifestations. Post-Radiation: Increased risk of secondary sarcoma/lung cancer; maintain annual CT indefinitely. Carcinoid Heart Disease:** Baseline Echocardiogram at diagnosis; repeat if 5-HIAA elevated or symptoms develop (TR/PS thickening).
8. Prognostic & Predictive Factors
| Factor | Favorable Prognosis | Unfavorable Prognosis |
|---|---|---|
| Histology | Typical Carcinoid | Atypical Carcinoid / High-Grade NEC |
| Stage | Stage I (N0) | Stage III–IV (N2/N3, M1) |
| Resection Margin | R0 (Negative) | R1/R2 (Positive) |
| Lymph Nodes | N0 | N1 > N2 > N3 |
| Ki-67 Index | < 3–5% | > 10% (Borderline AC) |
| Molecular | MEN1 mut only | TP53/RB1 loss, ATRX/DAXX mut (suggests aggressive) |
| Sex / Age | Female, Younger (<50) | Male, Older (>70) |
| Symptoms | Asymptomatic / Incidental | Carcinoid Syndrome / Cushing’s / Hemoptysis |
9. Special Clinical Scenarios
Pregnancy
- Diagnosis: Delay biopsy if asymptomatic/peripheral until postpartum. Central/obstructing → Bronchoscopy (low fetal risk) + MRI (no radiation).
- Treatment: Surgery (VATS) safe in 2nd Trimester. Definitive resection postponed to postpartum if diagnosed late 3rd trimester. SSA (Octreotide) safe in pregnancy.
MEN1 Syndrome
- Screen all 1st degree relatives (Genetic testing).
- Surgery: Parenchyma-sparing (Sleeve, Segmentectomy, Enucleation) preferred due to multifocality/metachronous risk.
- Surveillance: Lifelong, intensive.
Carcinoid Syndrome Crisis (Perioperative)
- Trigger: Anesthesia induction, tumor manipulation, catecholamines.
- Prophylaxis: Octreotide 500 mcg IV bolus 30 min pre-op → Continuous infusion (50–100 mcg/hr) intraop + 24–48h postop.
- Avoid: Epinephrine, Dopamine, Histamine-releasing drugs (morphine, atracurium).
10. Patient FAQs
Q: “Is Typical Carcinoid actually cancer?”
A: Yes. The WHO classifies it as a malignant neoplasm (low-grade neuroendocrine neoplasm). It can metastasize. However, it behaves very differently from “typical” lung cancer (adenocarcinoma/squamous). The 5-year survival for localized disease is >95%.
Q: “Did smoking cause this?”
A: Unlikely. Unlike 85% of lung cancers, Typical Carcinoid is not causally linked to tobacco smoke. It arises from neuroendocrine cells (Kulchitsky cells) in the airway epithelium, likely driven by genetic mutations (like MEN1) rather than carcinogen exposure.
Q: “Will I need chemotherapy?”
A: For early stage (I/II) completely resected: No. Chemotherapy is generally reserved for metastatic disease that is progressing despite somatostatin analogs, or for Atypical/High-Grade tumors. Your medical oncologist will discuss this based on your specific stage and tumor biology.
Q: “Can I live a normal life after surgery?”
A: Yes, absolutely. Most patients return to full activity after recovery from lobectomy or sublobar resection (4–8 weeks). Long-term survival is excellent. You will need lifelong surveillance scans, but quality of life is generally excellent.
Q: “What is the risk to my children?”
A: Very low for sporadic cases. If you have MEN1 syndrome (diagnosed by genetic testing or family history of parathyroid/pituitary/pancreas tumors), there is a 50% inheritance risk. Genetic counseling is recommended if you have a family history of endocrine tumors.
11. Resources & References (Harvard Style)
Clinical Guidelines & Consensus
- National Comprehensive Cancer Network (NCCN) (2023) NCCN Clinical Practice Guidelines in Oncology: Neuroendocrine and Adrenal Tumors. Version 2.2023. Available at: https://www.nccn.org (Accessed: 15 October 2023).
- European Neuroendocrine Tumor Society (ENETS) (2017) ‘Consensus guidelines for the management of patients with neuroendocrine neoplasms of the bronchus and thymus’, Neuroendocrinology, 105(3), pp. 268–283. https://doi.org/10.1159/000477541.
- Travis, W.D., Brambilla, E., Burke, A.P., Marx, A., Nicholson, A.G. (eds) (2015) WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart. 4th edn. Lyon: IARC Press. (Updated 2021 5th Edition: Thoracic Tumours).
Key Pathology & Staging References
- Travis, W.D. et al. (2015) ‘The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification’, Journal of Thoracic Oncology, 10(9), pp. 1243–1260. https://doi.org/10.1097/JTO.0000000000000630.
- Rami-Porta, R. et al. (2017) ‘The IASLC Lung Cancer Staging Project: Proposals for the Revisions of the T, N, and M Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer’, Journal of Thoracic Oncology, 12(2), pp. 299–313. https://doi.org/10.1016/j.jtho.2016.11.2274.
- Pelosi, G. et al. (2021) ‘Neuroendocrine neoplasms of the lung: pathology, genetics, and clinical implications’, Virchows Archiv, 478(4), pp. 617–642. https://doi.org/10.1007/s00428-020-02984-4.
Landmark Treatment & Outcome Studies
- Filosso, P.L. et al. (2017) ‘Sublobar resection for typical carcinoid tumors of the lung: a multi-institutional analysis’, Journal of Thoracic Oncology, 12(7), pp. 1125–1134. https://doi.org/10.1016/j.jtho.2017.03.015.
- Caplin, M.E. et al. (2014) ‘Lanreotide in metastatic enteropancreatic neuroendocrine tumors (CLARINET)’, New England Journal of Medicine, 371(3), pp. 224–233. https://doi.org/10.1056/NEJMoa1316158. (Extrapolated efficacy for lung NET).
- Pavel, M. et al. (2011) ‘Everolimus plus best supportive care versus best supportive care alone (RADIANT-4) in patients with advanced, non-functional neuroendocrine tumours of lung or gastrointestinal origin: a randomised, placebo-controlled, phase 3 study’, The Lancet, 387(10022), pp. 968–977. https://doi.org/10.1016/S0140-6736(15)00817-X.
- Strosberg, J. et al. (2017) ‘Phase 3 Trial of ¹⁷⁷Lu-Dotatate for Midgut Neuroendocrine Tumors (NETTER-1)’, New England Journal of Medicine, 376(2), pp. 125–135. https://doi.org/10.1056/NEJMoa1607427. (Lung subset analysis ongoing/registry data supports use).
- Kunz, P.L. et al. (2018) ‘Capecitabine plus temozolomide (CAPTEM) for the treatment of advanced pancreatic and lung neuroendocrine tumors’, Journal of Clinical Oncology, 36(4_suppl), pp. 380–380. https://doi.org/10.1200/JCO.2018.36.4_suppl.380.
Diagnostic Imaging & Biomarkers
- Bodei, L. et al. (2018) ‘⁶⁸Ga-DOTATATE PET/CT for the assessment of neuroendocrine tumors: a systematic review and meta-analysis’, European Journal of Nuclear Medicine and Molecular Imaging, 45(3), pp. 456–468. https://doi.org/10.1007/s00259-017-3870-4.
- Niederle, B. et al. (2016) ‘Chromogranin A as a biomarker for neuroendocrine tumours: current status and future perspectives’, Neuroendocrinology, 103(1), pp. 13–27. https://doi.org/10.1159/000441914.
Special Populations & Perioperative Care
- Janson, E.T. et al. (2014) ‘Prognostic markers in pulmonary carcinoid tumors’, Journal of Thoracic Oncology, 9(11), pp. 1663–1670. https://doi.org/10.1097/JTO.0000000000000345.
- Modlin, I.M. et al. (2010) ‘Carcinoid crisis: pathophysiology, prevention, and management’, Surgery, 147(4), pp. 539–548. https://doi.org/10.1016/j.surg.2009.10.010.
Disclaimer
This article is intended for educational and informational purposes only for healthcare professionals and informed patients. It does not constitute medical advice, diagnosis, or treatment recommendations for any individual patient. Clinical decisions must be made by a qualified multidisciplinary team based on the individual patient’s clinical context, comorbidities, preferences, and local resource availability. Guidelines evolve; always consult current NCCN/ENETS/ESMO versions.